<DOC>
	<DOCNO>NCT00431145</DOCNO>
	<brief_summary>Aim study show additional effect combine therapy niacin statins analyze number function EPCs stem cell population adiponectin well hsCRP level patient CAD .</brief_summary>
	<brief_title>Niacin As Secondary Prevention Of Coronary Artery Disease ( NASPOCAD )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Be least 18 year old , male female Have stable coronary artery disease ( i.e . acute event like myocardial infarction PTCA le 3 month ago ) LDL &gt; 100 mg/dl HDL &lt; 50 mg/dl Triglycerides &lt; 400 mg/dl No Nicotine abuse least 3 month Statintherapy 4 week Give write informed consent Have ability understand requirement study , agree able return require assessment . Women childbearing potential , pregnancy lactate Current participation another clinical trial Have severe concurrent illness ( e.g. , active infection , malignancy ) Have history alcohol drug abuse within 3 month admission factor make followup difficult unlikely . Have significant unexplained liver dysfunction chronic increase level transaminase ( ALT , AST ) Suffer myopathy , active peptic disease arterial bleeding Have know hypersensitivity niacin statin Are actually treat itraconazole , ketoconazole , HIVProteaseInhibitors , erythromycin , clarithromycin , telithromycin , nefazodone . Actual therapy ezetimibe Diabetes mellitus Type I</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>